Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III
To Learn More Call
201-510-0910
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Sponsor
MacroGenics
Protocol Number
MacroGenics Inc. CP-MGAH22-04
To Learn More Call
201-510-0910
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
ECOG-ACRIN
Protocol Number
EA1131
To Learn More Call
201-510-0910
Single Patient IND – Compassionate Use Niraparib (MK-4827)
Sponsor
Tesaro
Protocol Number
Tesaro Compassionate Use-Niraparib
To Learn More Call
201-510-0910
An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Protocol Number
2016-0162 Pedlar
To Learn More Call
201-510-0910
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Sponsor
Alliance
Protocol Number
Alliance A011202
To Learn More Call
201-510-0910
A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Innocrin
Protocol Number
INO-VT-464-CL-006
To Learn More Call
201-510-0910
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Type of Cancer
Breast Oncology
Sponsor
Alliance Foundation Trials
Protocol Number
AFT-58 (PATINA)
To Learn More Call
201-510-0910
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor
Alliance Pre-ECOG
Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS
To Learn More Call
201-510-0910
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Celldex
Protocol Number
CDX011-04
Cancer Diagnosis
Breast
Phase of Trial
Phase III